This study provides important insights into how the use of active drug PK assays, coupled with mechanistic follow-up, can inform and enable ongoing benefit/risk assessment for individuals participating in FIH dose-escalation trials. Translational studies that lead to a better understanding of the underlying biology of cognate T- and B-cell interactions, ultimately resulting in ADA development to novel biotherapeutics, are needed.
7 months ago
P1 data • Journal • Metastases
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TYRP1 (Tyrosinase Related Protein 1)